// App-Quantinova.ai

1589 : Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera Study

Researchers

Presenter

  • Nicole C.C. Them

Principal Investigators

  • Heinz Gisslinger

  • Veronika Buxhofer-Ausch

  • Robert Kralovics

  • Richard Greil

  • Josef Thaler

  • Ernst Schloegl

  • Guenther A. Gastl

  • Tiina Berg

  • Klaudia Bagienski

  • Oleh Zahriychuk

  • Christoph Klade

Medical Centers

  • CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

  • Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria

  • Dept. of Medicine I, Div. of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

  • IIIrd Medical Department, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria

  • Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University (IMU), Innsbruck, Innsbruck, Austria

  • Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria

  • Third Medical Department, Hanusch Hospital, Vienna, Austria

Locations

  • Austria

Companies

  • AOP Orphan Pharmaceu

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Myeloid neoplasms

  • Polycythemia vera

  • Myelofibrosis

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Interferon alpha

  • Hydroxyurea

  • Hydroxycarbamide

  • Interferon

  • Aspirin

  • Albyl-E

  • Ropeginterferonum alfa 2b

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved